FDA approves Gilead’s Veklury for COVID-19 patients with severe renal impairment
Gilead Sciences said that the US Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Veklury (remdesivir) usage in COVID-19 patients with severe renal impairment, encompassing those on dialysis. This approval positions Veklury as the sole antiviral COVID-19 treatment approved for use in all stages of renal disease. It’s estimated […]